Blood Test to Predict Response to Anti-TNF Treatment in Rheumatoid Arthritis
Tests a blood test to predict response to anti-TNF treatment in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Cross-validation of a Predictive Model of Response to Anti-TNF Alpha Based on Oxylipin Response in Rheumatoid Arthritis
Key facts
- Where
- Clermont-Ferrand, Paris, and Saint-Etienne, FranceSee the 3 sites
Where in France
- CHU Clermont-FerrandClermont-Ferrand, FranceNo longer taking part
- Hôpital Cochin APHPParis, FranceNo longer taking part
- CHU Saint-EtienneSaint-Etienne, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT06880146
- Record updated
- 17 March 2025
- Original description
The goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-TNF alpha treatment . The main questions it aims to answer is:Read full original descriptionShow less
Cross-validation of a Predictive Model of Response to Anti-TNF Alpha Based on Oxylipin Response in Rheumatoid Arthritis
The goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-TNF alpha treatment . The main questions it aims to answer is:
Is the predictive model created using oxylipins effective?
Participants starting anti-TNF alpha treatment will have a blood sample taken before starting treatment and 6 months afterwards.
Inclusion: Male or female patient aged 18 years or older with rheumatoid arthritis according to ACR EULAR 2010 criteria; Active disease as defined by DAS-28-CRP>3.2; Naive to targeted biologic or synthetic therapy; Rheumatologist's decision to start anti-TNFα treatment; Stable corticosteroid therapy ≤ 10 mg/day; Patient enrolled in or benefiting from a social security scheme; Patient who has given written informed consent to participate in the study.
Exclusion: Treatment with non-steroidal anti-inflammatory drugs in the 2 weeks prior to enrolment; Contraindication to biological treatment (cancer or history of cancer); Protected persons (pregnant and/or breastfeeding women, persons under guardianship or conservatorship).